LYEL
HEALTHCARELyell Immunopharma Inc
AI Insight
What's Moving LYEL Today?
No stock-specific AI insight has been generated for LYEL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.46$45.00
$12.63
Fundamentals
Market Cap$297M
P/E Ratio—
EPS$-13.64
Dividend Yield—
Dividend / Share—
ROE-80.8%
Profit Margin—
Debt / Equity—
Trading
Volume152K
Avg Volume (10D)—
Shares Outstanding23.3M
LYEL News
23 articles- Innovative Cellular Therapeutics (LYEL) crosses 12.3% ownership after milestoneStock Titan·Jun 18, 2026
- Lyell Immunopharma president and CEO Lynn Seely sells $7,337 in stockInvesting.com·Jun 16, 2026
- Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 CongressYahoo Finance·Jun 12, 2026
- Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Jun 9, 2026
- Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 StudyYahoo Finance·Jun 8, 2026
- Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 ExpansionYahoo Finance·Jun 8, 2026
- Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 CongressYahoo Finance·Jun 4, 2026
- Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerYahoo Finance·Jun 4, 2026
- Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026Yahoo Finance·Jun 1, 2026
- Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline AdvancesMarketbeat·May 27, 2026
- Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)Yahoo Finance·May 19, 2026
- Lyell Immunopharma Announces Participation in May Investor ConferencesYahoo Finance·May 12, 2026
- Explore Investments/Jeff Bezos report 6.6% stake in Lyell (LYEL)Stock Titan·May 9, 2026
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026Yahoo Finance·May 6, 2026
- Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 7, 2026
- Lyell Immunopharma: Q4 Earnings SnapshotYahoo Finance·Mar 12, 2026
- Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial ResultsYahoo Finance·Mar 12, 2026
- Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business OfficerYahoo Finance·Mar 9, 2026
- Lyell Immunopharma Announces Participation in March Investor ConferencesYahoo Finance·Feb 23, 2026
- Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechsBiopharmadive·Feb 13, 2026
- Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell LymphomaYahoo Finance·Feb 12, 2026
- The Zacks Analyst Blog Mineralys, Lyell, Insmed and NektarYahoo Finance·Dec 26, 2025
- 4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to GrowYahoo Finance·Dec 24, 2025
All 23 articles loaded
Price Data
Open$11.88
Previous Close$11.97
Day High$13.02
Day Low$11.66
52 Week High$45.00
52 Week Low$8.46
52-Week Range
$8.46$45.00
$12.63
Fundamentals
Market Cap$297M
P/E Ratio—
EPS$-13.64
Dividend Yield—
Dividend / Share—
ROE-80.8%
Profit Margin—
Debt / Equity—
Trading
Volume152K
Avg Volume (10D)—
Shares Outstanding23.3M
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—